In sarcoidosis, elevated inflammatory proteins in plasma are evident years before the onset of disease, according to study findings published in the European Respiratory Journal.

Results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and congestion in CRSwNP.